vaccine adjuvants
Blueprints of Signaling Interactions between Pattern Recognition Receptors: Implications for the Design of Vaccine Adjuvants
6
Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands as Influenza Virus Vaccine Adjuvants Induce Rapid, Sustained, and Broadly Protective Responses
15
CONSTRUCTION AND CHARACTERIZATION OF NON-TOXIC BACTERIAL ENTEROTOXINS AS VACCINE ADJUVANTS
106
Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome
6
Interleukin-1 Family Cytokines as Mucosal Vaccine Adjuvants for Induction of Protective Immunity against Influenza Virus
10
The role of TLR2 in cutaneous leishmaniasis and as a target for vaccine adjuvants
197
Computer aided prediction of antigen presenting cell modulators for designing peptide based vaccine adjuvants
15
TLR, NLR agonists, and other immune modulators as infectious disease vaccine adjuvants
24
Non-ionic surfactant-based organogels: Their structures and potential as vaccine adjuvants
210
Metal organic frameworks : from anticancer multifunctional drug delivery systems to novel vaccine adjuvants
182
Polyethylenimine-based micro/nanoparticles as vaccine adjuvants
18
Choice and design of adjuvants for parenteral and mucosal vaccines
24
Bacterial ghosts as adjuvants: mechanisms and potential
13
Beyond antigens and adjuvants: formulating future vaccines
11
Designing liposomal adjuvants for the next generation of vaccines
30
Phase I Evaluation of Intranasal Trivalent Inactivated Influenza Vaccine with Nontoxigenic Escherichia coli Enterotoxin and Novel Biovector as Mucosal Adjuvants, Using Adult Volunteers
9
Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers
9
Adjuvants : an essential component of neisseria vaccines
5
Drift potential of UAV with adjuvants in aerial applications
5
Institutional Policies and Guidelines on Adjuvants and Antibody Production
12